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Abstract
Background: Foamy virus Bel1/Tas trans-activators act as key regulators of gene expression and
directly bind to Bel1 response elements (BRE) in both the internal and the 5'LTR promoters leading
to strong transcriptional trans-activation. Cellular coactivators interacting with Bel1/Tas are
unknown to date.
Results: Transient expression assays, co-immunoprecipitation experiments, pull-down assays, and
Western blot analysis were used to demonstrate that the coactivator p300 and histone
acetyltransferase PCAF specifically interact with the retroviral trans-activator Bel1/Tas in vivo. Here
we show that the Bel1/Tas-mediated trans-activation was enhanced by the coactivator p300,
histone acetyltransferases PCAF and SRC-1 based on the crucial internal promoter BRE. The Bel1/
Tas-interacting region was mapped to the C/H1 domain of p300 by co-immunoprecipitation and
pull-down assays. In contrast, coactivator SRC-1 previously reported to bind to the C-terminal
domain of p300 did not directly interact with the Bel1 protein but nevertheless enhanced Bel1/Tas-
mediated  trans-activation. Cotransfection of Bel1/Tas and p300C with an expression plasmid
containing the C/H1domain partially inhibited the p300C-driven trans-activation.
Conclusions: Our data identify p300 and PCAF as functional partner molecules that directly
interact with Bel1/Tas. Since the acetylation activities of the three coactivators reside in or bind to
the C-terminal regions of p300, a C/H1 expression plasmid was used as inhibitor. This is the first
report of a C/H1 domain-interacting retroviral trans-activator capable of partially blocking the
strong Bel1/Tas-mediated activation of the C-terminal region of coactivator p300. The potential
mechanisms and functional roles of the three histone and factor acetyltransferases p300, PCAF, and
SRC-1 in Bel1/Tas-mediated trans-activation are discussed.
Background
In the sequential model of transcriptional regulation
including viral trans-activation, coactivators CBP/p300
require concerted action of multiple protein factors pro-
vided the nucleosomal structures allow access to the DNA
template [1-3]. The factors that interact with coactivators
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encompass sequence-specific DNA binding activators,
non-DNA binding coactivators, and essential components
of the basal transcriptional machinery. Two large, closely
related human proteins, p300 and CBP, were identified
and shown to function as versatile signal integrators of
many transcription factors to facilitate transcriptional
activation or repression, and, in addition, as connectors of
multiple transduction pathways. Both proteins contain
several conserved domains that include three Cys/His-rich
(C/H1, C/H2, and C/H3) domains, the histone acetyl-
transferase (HAT), KIX, and Gln-rich (Q) domains among
others (Fig. 1) [2,4,5]. It is mainly due to these domains
that a plethora of transcriptional activators interact with
p300/CBP. Thus, p300/CBP coactivators act as a physical
and functional scaffold or bridge between various cellular
or viral trans-activators and the basal transcriptional
machinery. Both proteins function by mediating positive
or negative cross talk between different signaling path-
ways and participate in fundamental cellular processes
that include embryonic development, cell growth, differ-
entiation, and apoptosis. In addition, they can act as
tumor suppressors and, last but not least, directly interact
with diverse viral trans-activators to facilitate virus replica-
tion or viral activator-mediated transformation [6,7].
Several models have been proposed to explain transcrip-
tional activation. Coordinated recruitment of coactivators
by diverse transcriptional activators to specific promoter
target sites has been shown by a collective effort of many
groups [8]. According to the models, different coactivators
either modify chromatin structure by altering the nucleo-
somal DNA thereby affecting its accessibility to DNA-
binding proteins or, alternatively, form complexes with
HAT activities that by acetylation of specific Lysines in
histone N-terminal tails weaken interactions between
DNA and the histone octamer. Moreover, the HAT activi-
ties of some coactivators acetylate non-histone substrates
such as viral and cellular trans-activators, for instance p53
[9].
Diverse viral trans-activator proteins were found to inter-
act with distinct domains of p300/CBP and PCAF. Promi-
nent among them are the early adenoviral E1A antigen
[10,11], Epstein-Barr virus protein EBNA-2 [12], and
human T-cell leukemia virus oncoprotein Tax [13,14].
Several other modifications including methylation, phos-
phorylation, and ubiquitination lead to either diminished
or increased DNA binding of the activators that, in turn,
will result in either a repression or activation of gene
expression. In addition, both coactivators were reported
to interact with additional HAT enzymes, namely PCAF
and SRC-1 [15,16].
The apparently nonpathogenic primate foamy viruses
(PFV) show a wide host range and tissue tropism and have
been developed into vectors that efficiently transduce
SCID-repopulating cells [17]. The PFV Bel1/Tas protein
has been characterized as a transcriptional trans-activator
of the acidic class and is known to directly interact with its
responsive elements (BRE) [18,19]. Bel1/Tas is a nuclear
protein and acts as the key regulator absolutely required
for virus replication. The minimal Bel1-specific DNA tar-
get site is 27 base-pairs long and located within the inter-
nal promoter (IP.BRE) upstream of the second cap site
that is part and parcel of the second PFV transcription unit
[20]. Additional Bel1/Tas DNA target sites in the LTR
region of the PFV DNA genome were not analyzed in this
study. The acidic trans-activation domain (TAD) was
mapped to the C-terminus of Bel1 with little if any protein
homology to other FV Bel1/Tas proteins from different
species. Previously, we identified the nuclear factor 1
(NF1) as a repressor of Bel1/Tas-mediated trans-activation
[21]. This repression was due to the fact that the specific
family members NF1-C and -X interacted with parts of the
IP.BRE and its flanking sequences. Since the NF1-medi-
ated repression of the promoter of mouse mammary
tumor virus was abrogated by distinct coactivators [22],
we investigated which of the known coactivators and HAT
proteins were capable of interacting with the PFV Bel1/Tas
activator in the context of the IP.BRE promoter that is
absolutely required for virus replication [20]. Here we
report that the Bel1/Tas DNA binding protein functionally
interacted with p300 and with the well-known HAT factor
PCAF. In addition, SRC-1 enhanced Bel1/Tas trans-activa-
tion. This is the first time that these cellular coactivators
have been shown to interact with the Bel/Tas1 trans-acti-
vator protein. Furthermore, Bel1/Tas binding to the C/H1
domain of p300 and coactivator-driven trans-activation
seem to follow a unique pathway.
Results
Coactivator p300 enhances Bel1/Tas-mediated activation
To examine whether p300 (Fig. 1, first line) enhanced the
ability of Bel1 to trans-activate the Bel1 internal promoter
(IP.BRE), transient reporter gene assays were performed.
The IP.BRE that extends from -1 to -192 of the second cap
site of the PFV genome was cloned into the pGL3-pro-luc
reporter plasmid [21]. The results of the luc assays showed
that full-length p300FL enhanced Bel1/Tas-mediated acti-
vation in an apparently nonlinear fashion (Fig. 2, upper
left panel). To monitor the expression level of the p300
protein, Western blot analysis was carried out in parallel
with increasing concentrations of the coactivator at fixed
concentrations of the pbel1s expression plasmid that car-
ries the retroviral trans-activator under the control of the
CMV-IE promoter. The results of immunoblotting shown
in the lower left panel of Figure 2 revealed that Bel1/Tas
was expressed at similar levels, as expected, and p300FL
expression levels proportional to the input. In parallel
experiments, truncated p300 forms, p300N and p300M,BMC Molecular Biology 2004, 5:16 http://www.biomedcentral.com/1471-2199/5/16
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were also assayed and yielded moderate levels of enhance-
ment of Bel1/Tas-mediated activation lower than those of
p300FL (Fig. 3). Unexpectedly, the most extensive level of
enhancement of Bel1/Tas-induced activation was reached
with the C-terminal region p300C (Fig. 2, upper right
hand panel). Again, Western blot analysis of p300C
showed that expression levels of p300C protein increased
proportionately to the transfected plasmid DNA while
Bel1/Tas expression levels were unchanged (Fig. 2, lower
right panel). The precise boundaries of the three p300 ver-
sions used are shown in Figure 1. The p300 bands marked
by arrows are likely due to modified p300 proteins that
are known to be modified by phosphorylation, acetyla-
tion and sumoylation (2, 5, 26). We next sought to deter-
mine whether the enhancing effect of p300 on Bel1/Tas-
mediated activation was due to a physical interaction with
the Bel1/Tas protein.
Bel1/Tas interacts with p300 in vivo
To examine whether the coactivator p300 interacts with
the retroviral activator Bel1/Tas, binding of p300FL to the
Bel1/Tas protein was analyzed by immune precipitation.
293T cells were cotransfected with the full-length p300FL
and pbel1s expression plasmids and metabolically
labeled with [35S]-Methionine and -Cysteine. Cellular
lysates were precleared and subjected to immunoprecipi-
tation with an antibody directed against the Bel1/Tas pro-
tein except for that in lane 1 (Fig. 4). After separation by
SDS-PAGE and exposure, the resulting autoradiogram
showed that the Bel1-specific antibody had effectively pre-
cipitated the p300FL-Bel1/Tas protein complex at both
p300FL DNA concentrations of 10 µg (Fig. 4, lane 3) and
20 µg (lane 6). In the control where pbel1s was omitted
the immune precipitation did not reveal any band compa-
rable in size to p300 (lane 4). In the immunoprecipitation
shown in lane 1 instead of an antibody against Bel1/Tas,
an antibody against p300 was used and showed that the
bands marked in Fig. 4 was p300 (lane 1).
To check the data obtained, co-immunoprecipitations
were performed with non-labeled 293T cells followed by
Western blot analysis. Cellular lysates were prepared from
293T cells separately cotransfected with pbel1s and each
one of the three truncated p300 expression plasmids,
p300N, p300M, or p300C and analyzed as described
above. A polyclonal antibody directed against the Bel1/
Tas protein was used in the co-immunoprecipitation fol-
lowed by immunoblotting with a monoclonal antibody
directed against the FLAG epitope fused in-frame with the
N-terminus of the three truncated p300 versions. The
results shown in Figure 5 indicate that p300N protein spe-
cifically interacted with Bel1/Tas (lane 1) whereas the
middle and C-terminal regions, p300M and p300C,
respectively, do not seem to bind to Bel1/Tas under the
conditions used (Fig. 5, lanes 3 and 5). This experiment
was repeated several times and yielded the same result. In
the controls, pbel1s was omitted in the cotransfections
(lanes 2, 4, and 6).
Mapping of the p300-Bel1/Tas interaction domain
We next determined which N-terminal p300 domain was
responsible for the specific interaction with the Bel1/Tas
protein. Different truncated versions of p300N (Fig. 1)
were prepared, cloned, and subjected to separate immu-
noprecipitations and Western blot analyses as described
above for p300N. In addition, two different GST fusion
proteins that contained either the C/H1 or KIX domain
were bacterially expressed, purified, and analyzed (Fig. 1).
Two different expression plasmids p300N-C/H1-∆KIX
that lacked the KIX but still expressed the C/H1 domain
were capable of binding Bel1/Tas (Fig. 6, right panel, lanes
2 and 3). In contrast, the results shown in Fig. 6, lanes 4
and 5, revealed that the plasmid p300-∆C/H1-∆KIX that
Coactivator p300 enhances Bel1/Tas-mediated trans-activa- tion Figure 1
Coactivator p300 enhances Bel1/Tas-mediated trans-
activation. Simplified schematic drawing of p300 domains 
and structure of deletion mutants (not drawn to scale). 
Characterized domains of p300 [2, 5] relevant for this report 
are highlighted by differently marked boxes: the FLAG 
epitope upstream of the N-terminus of p300 is marked by 
shaded boxes in constructs no. 1 through 8, the C/H1 and 
KIX domains by black and striped boxes, respectively. Num-
bers above the rectangles indicate the number of amino acids 
of p300 and its derivatives. The intrinsic HAT domain of 
p300 is depicted between the C/H2 and C/H3 domains; addi-
tional HATs PCAF and SRC-1 reported to associate with the 
distinct p300 regions [8, 24, 25] are indicated as rectangles 
above p300. The domain marked "Q" is the glutamine-rich 
domain of p300. Construct no. 5 has a deletion between the 
C/H1 and KIX domain (broken line). Constructs no. 9 and 10 
contain the GST-C/H1 and GST-∆C/H1-KIX fusion proteins; 
partial shadings mark GST regions.
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Coactivator p300 enhances Bel1/Tas-mediated activation Figure 2
Coactivator p300 enhances Bel1/Tas-mediated activation. Transient expression assays were performed with pGL3-luc 
plasmids containing the internal PFV BRE promoter (-1 to -192) after transfection of the pCMV-bel1s expression plasmid alone 
or separate cotransfection with p300FL and p300C expression plasmids [4]. Normalized luc activities are shown as fold activa-
tion in upper panels (for details, see Methods). Expression levels of Bel1/Tas and p300 proteins after cotransfection of 293T 
cells with increasing p300FL and p300C DNA concentrations and pbel1s DNA of 1.0 µg. Aliquots of the cellular lysates used 
for luc assays shown in upper panel were in parallel subjected to immunoblot analysis with monoclonal antibody against the 
FLAG epitope of the p300FL protein (lower left panel), and against the p300C protein (lower right hand panel). Polyclonal anti-
body against Bel1 was used for Bel1/Tas expression (bottom lanes in lower panels).
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Reporter gene assays of shortened p300 expression plasmids Figure 3
Reporter gene assays of shortened p300 expression plasmids. Transient expression assays were done as described 
under Fig. 2 except for that cotransfections were carried out with p300N and p300M plasmids; for boundaries of p300, see Fig. 
1.
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lacks both the C/H1 and KIX domains but retains the
short N-terminal region of 196 amino acids did not bind
Bel1/Tas. The expression levels of the five constructs were
monitored by immunoblot analysis and exhibited the
expected bands of p300-derived proteins (Fig. 6, left
panel).
To unambiguously demonstrate that the C/H1 domain of
p300 is the Bel1/Tas-interacting region, we performed
pull-down assays with two pGST-C/H1 and pGST-∆C/H1-
KIX fusion proteins (Fig. 1, constructs no. 9 and 10). The
results revealed that purified pGST-C/H1 clearly inter-
acted with Bel1/Tas as shown in Fig. 7, lane 2 whereas the
Direct physical interaction of Bel1/Tas with p300 determined  by co-immunoprecipitation Figure 4
Direct physical interaction of Bel1/Tas with p300 
determined by co-immunoprecipitation. Bel1/Tas binds 
to p300 in vitro and in vivo. After transfection of 293T cells 
with expression plasmids pbel1s and p300FL, cells were 
labeled with [35S]-Methionine plus [35S]-Cysteine. Cellular 
extracts were precipitated, separated by SDS-PAGE and 
exposed. Protein p300FL is marked by bold arrowhead (lanes 
1, 3, and 6). In the control, pbel1s was omitted (lane 4). 
Arrowheads indicate the following protein size markers (M, 
lanes 2 and 5): myosin of apparent molecular mass of 236, 
phosphorylase b of 97, and BSA of 66 kDa.
1    2     3     4      5      6
p300 FL
p300 FL 10 20 20 µg
pbel1s + +
M
Myosin
Phosphorylase b
BSA
20
+
M
Analysis of physical interaction of Bel1/Tas with truncated  forms of p300 Figure 5
Analysis of physical interaction of Bel1/Tas with trun-
cated forms of p300. After cotransfection of 293T cells 
with 2 µg pbel1s, and, separately with 2 µg each of p300N, 
p300M, and p300C expression plasmids, cellular extracts 
were prepared in parallel, divided into equal parts, and ana-
lyzed by co-immunoprecipitation and Western blotting. 
Lysates were precipitated with anti Bel1/Tas antibody and 
the Western blot was developed with a monoclonal anti-
FLAG antiserum. The three arrows in the middle panel mark 
the correct sizes of the p300N, p300M, and p300C proteins 
(two blots pasted together). Controls for each p300 plasmid 
without pbel1s are in lanes 2, 4, and 6. Lower part confirms 
that the p300N protein specifically binds the Bel1/Tas pro-
tein (lane1, marked by arrow); two blots pasted together.
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pGST-∆C/H1-KIX and a control GST plasmid did not
(lanes 1 and 3).
To summarize this part, our data show that p300 physi-
cally interacted with Bel1/Tas in vivo, and that the C/H1
domain of p300 was responsible for this interaction at
least in vitro.
Effect of the Bel1-C/H1 domain on Bel1/Tas-mediated 
activation by p300C
To gain more insight into the mechanism of the C/H1-
Bel1 complex that affects3 p300C-mediated activation,
cotransfections of pbel1s and p300C with expression plas-
mid p300N-C/H1-∆KIX were carried out (Fig. 1, construct
6). Cellular lysates of 293T cells were prepared and luci-
ferase assays performed. Cotransfections of fixed concen-
trations of the pbel1s, 0.5 µg, with the pC/H1-∆KIX
expression plasmid did not enhance p300C-mediated
trans-activation (Fig. 8, lanes 5, 7, 9, 11, and 13). In con-
trast, the expression of the C/H1 domain resulted in a par-
tial suppression of the p300C-driven activation at higher
C/H1 domain concentrations (Fig. 8). Similar degrees of
inhibition were obtained when lower Bel1/Tas concentra-
tions were used. Western blot analysis was carried out in
parallel with increasing concentrations of the coactivator
to ascertain Bel1/Tas expression (data not shown). The
Mapping of the p300 Bel1/Tas-interaction domain Figure 6
Mapping of the p300 Bel1/Tas-interaction domain. 
The p300 expression plasmids, constructs no. 2, and 5 to 8 
shown in Fig. 1 were analyzed by immunoprecipitation as 
described above for p300N. The right hand panel shows the 
results of immunoblotting obtained after reaction with the 
monoclonal antibody against the FLAG epitope; arrows and 
asterisks mark the Bel1/Tas-interacting protein bands from 
cellular extracts of pbel1s-cotransfected cells (lanes 1–3); 
intentionally overexposed to visualize the marked bands in 
lanes 1 and 2. The left panel presents the Western blots of 
the five recombinant p300N plasmids used for separate co-
immunoprecipitations. Numbers in brackets refer to Fig 1.
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Bel1/Tas interacts with GST-C/H1 fusion proteins detected  by GST pull-down assays Figure 7
Bel1/Tas interacts with GST-C/H1 fusion proteins 
detected by GST pull-down assays. The recombinant 
GST-C/H1 and GST-∆C/H1-KIX proteins were expressed in 
E. coli BL21 cells and purified by binding to glutathione Sepha-
rose 4B. Each GST-fusion protein bound to glutathione 
Sepharose 4B was separately mixed with lysates obtained 
from pbel1s-transfected 293T cells. After incubation and 
extensive washing with the binding buffer, bound proteins 
were eluted, separated by SDS-PAGE, and visualized by stain-
ing (upper panel); immunoblotting was carried out with an 
antibody against Bel1/Tas protein (lower panel).
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inhibition by the C/H1 domain explains why the level of
trans-activation of p300N and p300FL did not reach the
full extent of p300C-driven activation.
PCAF interacts with Bel1/Tas
We next analyzed whether different HAT-expressing genes
such as GCN5, PCAF, and SRC-1 were able to enhance
and interact with Bel1/Tas. Transient luciferase gene
assays with pGCN5 expression plasmids did not affect
Bel1/Tas-mediated activation (data not shown). In
contrast, when the HAT PCAF expression plasmid was
used for co-expression, an enhancement of Bel1/Tas-
induced activation was detectable at a concentration of
0.02  µg PCAF DNA and 0.5 µg pbel1s (Fig. 9, upper
panel). At higher PCAF DNA concentrations, repression of
Bel1/Tas-mediated activation was observed. When the lev-
els of PCAF and Bel1/Tas protein expression was deter-
mined by Western blot analysis, a decreased level of the
Bel1/Tas expression was detected that was likely due to
degradation (Fig. 9, lower panel). The band of the PCAF
protein corresponded to the correct size of about 95 kDa
(marked by arrow).
We next analyzed the potential interaction between the
Bel1/Tas and PCAF proteins by carrying out co-immuno-
precipitation with 293T cellular lysates that had been
cotransfected with 2.0 µg pbel1s and pCI-PCAF expres-
sion plasmids, followed by immunoreaction with an anti-
body against Bel1 and subsequent immunoblotting with
an anti-FLAG antibody to detect PCAF. The results showed
that PCAF did indeed interact with the PFV Bel1/Tas acti-
vator (Fig. 10, lane 2). As control, an
Effect of p300-C/H1 domain expression on enhancement of  p300C-mediated trans-activation Figure 8
Effect of p300-C/H1 domain expression on enhance-
ment of p300C-mediated trans-activation. Transient 
expression assays with pGL3-luc containing the internal BRE 
promoter after cotransfection of the p300C and pC/H1 
expression plasmids with pbel1s.
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immunoprecipitation and Western blot analysis was
performed with the PCAF plasmid in the absence of
pbel1s (Fig. 10, lane 1). The result showed that a PCAF
band was not detectable under the conditions used.
To determine if an additional HAT protein, SRC-1,
affected Bel1/Tas-mediated activation, transient reporter
gene expression assays were carried out after cotransfec-
tion of 293T cells with the coactivator SRC-1a and 0.5 µg
pbel1s. Surprisingly, a relatively strong enhancement of
Bel1/Tas-mediated activation was detected (Fig. 11, upper
panel). The level of expression of both SRC-1a and Bel1/
Tas proteins was determined and found to be approxi-
mately proportional to the input (Fig. 11, lower panel).
To assess whether SRC-1a was able to physically interact
with the Bel1/Tas protein, immunoprecipitations and
Western blot analysis were carried out under different
conditions. The specificity of SRC-1a was ascertained by
using monoclonal antibody directed against SRC-1a in
control reaction. However, evidence for an interaction
Physical interaction of PCAF with Bel1/Tas Figure 10
Physical interaction of PCAF with Bel1/Tas. Co-immu-
noprecipitation and immunoblot analysis of pCI-FLAG-PCAF-
cotransfected 293T cells with pbel1s DNA (lane 2). The cel-
lular lysates were incubated with an anti Bel1/Tas antibody 
and treated as described in the legend to Fig. 5 except for 
that an antibody directed against the FLAG epitope of PCAF 
was used for immunoblotting. In the control, cotransfection 
was done without pbel1s (lane 1).
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Coactivator SRC-1 enhances Bel1/Tas-mediated trans-activa- tion Figure 11
Coactivator SRC-1 enhances Bel1/Tas-mediated 
trans-activation. Reporter luc gene expression assays with 
pGL3-luc plasmids containing the internal PFV BRE promoter 
after cotransfection of pCR3.1-FLAG-SRC-1a with the pbel1s 
expression plasmid (upper panel). Immunoblotting of 293T 
cellular extracts cotransfected with the SRC-1a and pbel1s 
expression plasmids (lower panel).
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between the SRC-1a protein and Bel1/Tas was not
obtained.
Discussion
It was previously reported that Bel1/Tas is capable of
inducing the expression of many cellular genes [23].
While it is known that Bel1/Tas binds directly and to a
large number of DNA target sites [18-21], the mechanism
of activation and the identity of the cellular partner mole-
cules of Bel1/Tas remained unknown. As a first step, we
have sought to identify the cellular proteins that interact
with the PFV retroviral trans-activator and mediate its
activating potential. The data presented here show that
the coactivators p300 and HAT PCAF physically bound
Bel1/Tas in vitro and both enhanced Bel1/Tas-mediated
activation whereas SRC-1 enhanced with Bel1/Tas activa-
tion without direct binding. According to our data, Bel1/
Tas specifically interacted with the C/H1 domain of p300,
although we cannot rule out binding to other p300
domains with much lower affinity not detectable under
the rather harsh conditions of co-immunoprecipitation
used here.
When the levels of the relative luciferase activity of
p300FL and its three shortened versions are compared, it
is noteworthy that p300C reached the highest level of
enhancement of Bel1/Tas-mediated activation (Fig. 2).
Besides its intrinsic HAT activity, p300C contains both the
intact C/H3 and Q domains that interact with the HAT
enzymes PCAF and SRC-1, respectively [10,24,25]. These
three HAT enzymes are likely responsible for the large
enhancement of the observed trans-activation either
directly by acetylation of Bel1/Tas or indirectly by histone
acetylation, or both. In contrast to p300C, p300N and
p300M do not possess any HAT activities nor do they bind
to HAT-containing interaction partners. On the other
hand, it is well known that p300 and its three subregions
bind a plethora of various partner molecules leading to
either activation or repression of transcription. Since the
high level of p300C-mediated activation was partially
inhibited in cotransfections with C/H1 and pbel1s, com-
petition for Bel1/Tas between the C/H1 and the p300C-
terminal interaction partners PCAF and SRC-1 cannot be
ruled out so that both direct and indirect mechanisms
might be responsible for the relative increase in Bel1/Tas-
mediated activation by p300C. When Bel1/Tas binds to
the C/H1 domain, the degree of Bel1/Tas acetylation may
be much lower, since the protein surface of Bel1/Tas may
be occluded and, hence less accessible. Some residual Bel1
acetylation might still occur by endogenous p300 and
PCAF. Other factors might play additional roles. The abil-
ity of full-length p300 to trans-activate Bel1/Tas was rela-
tively low for two reasons. First, the transfection efficiency
of the full-length p300 is very low because of its large
plasmid size, and the concentration of endogenous p300
is limiting. Secondly, the activation loop of p300 HAT is
not fully activated by auto-acetylation as required for full
trans-activation [26].
Since the relative activation by SRC-1 was not as high as
that of p300C, we consider the HAT activity of PCAF as
one of the major players of Bel1/Tas-mediated trans-acti-
vation. This result is supported by the observed enhance-
ment of Bel1/Tas activation after cotransfection with
PCAF that resulted in higher levels of Bel1 acetylation
thereby leading to increased binding to the IP.BRE [J.
Bodem, personal communication]. Thus, the observed
high level of enhancement of p300C might be due to the
synergistic effects brought about by formation of ternary
p300C-PCAF-Bel1 and binary p300C-SRC complexes,
respectively. In these multimeric protein complexes, Bel1/
Tas binds p300C indirectly through PCAF. Consistent
with the HAT activities of PCAF and p300, we detected
acetylated Bel1/Tas in pbel1s-transfected 293T cells using
monoclonal antibody against acetyl-Lysine after immu-
noblotting (our unpublished data). It is intriguing that
the distribution of the closely spaced Lysines of Bel1/Tas
apparently mimics the correspondingly spaced Lysines in
histones. This observation is further complicated by our
observation that cotransfection with higher levels of PCAF
led to a reduced stability of Bel1/Tas (Fig. 9). We assume
that PCAF acetylates or even hyper-acetylates the Bel1/Tas
protein at closely spaced Lysines in analogy to other
activators reported previously [9]. The decreased stability
of acetylated Bel1/Tas might indicate that modified Bel1/
Tas is less stable than the unmodified form. This observa-
tion adds an additional layer of combinatorial regulation
to Bel1/Tas-mediated trans-activation.
It is intriguing that some viral trans-activators interact with
more than a single p300 domain [10,14]. However, Bel1/
Tas might recruit a second interacting region of p300
through binding PCAF (Fig. 10) that is known to interact
with a p300 domain different from the C/H1 domain
(Fig. 1) [10]. The complex nature of p300-Bel1/Tas inter-
actions reported here might serve to strengthen the overall
binding affinity between Bel1/Tas and the PCAF interac-
tion domain of p300 within a larger transcriptional com-
plex [27]. PCAF is known to specifically acetylate distinct
Lysine residues of a subset of core histones and thereby
regulate the transcriptional activity of many genes
depending on the genetic context. It is well documented
that acetylation, methylation and other covalent histone
modifications are essential signals for the regulation of
transcription [28].
It remains to be seen whether the stronger level of
enhancement of p300C is a special if not unique feature
of Bel1/Tas activation and due to over-expression or to
repressive effects of other p300-interacting protein factorsBMC Molecular Biology 2004, 5:16 http://www.biomedcentral.com/1471-2199/5/16
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that cannot bind to the truncated p300 protein. Alterna-
tively, many other factors were reported to bind to the C-
terminal domains of p300 that also encompass general
transcription factors TBP and TFIIB proteins that might
also be responsible for the enhancement observed here [1-
3].
In search of viral and cellular activators that are compara-
ble with the ability of Bel1/Tas to interact with the C/H1
domain of p300, we found one case. A report indicates
that EBNA-2 protein shares many features with Bel1/Tas
that include the C-terminal acidic activation domain as
well as the abilities to bind both the C/H1 domain and
PCAF [12]. There remain two differences, however. First,
EBNA-2 binds to both the C/H1 and the C/H3 domain,
and, secondly, PCAF does not coactivate EBNA-2 in strong
contrast to Bel1/Tas [12].
Of note, an additional HAT enzyme, GCN5, did not inter-
act with Bel1/Tas when tested in reporter genes assays
indicating that only distinct HAT sets such as those
identified in this report specifically interact with Bel1/Tas
in trans-activation. The precise roles of the HAT activities
of PCAF, p300, and SRC-1 during Bel1/Tas-mediated
trans-activation remain to be addressed in future studies.
Conclusions
Coactivators PCAF and p300 were identified to physically
and functionally interact with the spumaviral Bel1/Tas
trans-activator. Coactivator SRC-1 was found to strongly
enhance Bel1/Tas-mediated trans-activation. The C/H1
domain of p300 was responsible for binding the retroviral
activator and found to partially inhibit the p300-driven
trans-activation.
Methods
Antibodies
Mouse monoclonal antibodies directed against the FLAG
epitopes of p300FL, p300N, p300M, p300C, and PCAF
were purchased from Sigma, rabbit polyclonal antibodies
against the N-terminal p300FL, the C-terminal p300C,
and SRC-1a from Santa Cruz Biotechnology. The polyclo-
nal serum direct against Bel1/Tas was used as described
previously [23]. Typically, 5 µl of each antiserum was used
for each immunoprecipitation. Monoclonal antibody
against acetyl-Lysine was purchased from Sigma.
Plasmids, cells, transfections, and metabolic labeling
Plasmids pUC18, pCMVβ-gal, pbel1s [29], pGL3-pro-IP.
BRE (-1 to -192), pCI-FLAG-p300FL, pCI-FLAG-p300N,
pCI-FLAG-p300M, pCI-FLAG-p300C [4], and pCI-FLAG-
PCAF [29] were separately, or in the combinations indi-
cated, transfected into 293T cells using Lipofectamine
2000 (Invitrogen). In general, unless otherwise indicated,
0.1 – 10 µg plasmid DNA were transfected into 293T cells
grown in Petri dishes with a diameter of six cm. Full-
length pCI-FLAG-300FL plasmids and three different
shortened versions (Fig. 1, constructs no. 1 to 4) were
grown in E. coli, DH5α cells [4]. The PFV internal pro-
moter was constructed by PCR-mediated amplification of
the defined promoter fragments as reported previously
[19,21]. Recombinant clone p300N-C/H1-∆KIX* (con-
struct no. 5, Fig. 1), was constructed by first generating
two PCR products with pCI-p300FL as template using the
sense (s) and antisense (as) primers s1: 5'-CTTATGGT-
TCACCATATACTCAGAATCC-3', as1: AAACTGGAAC-
CATGCCTGCATTTCTCTTATCACC-3', s2: 5'-
GAAATGCAGGCATGGTTCCAGTTTCCAT-3', and as2: 5'-
GGAAGGAACTGGCCCTGGTTGGAAGGCTGTTG-3' to
amplify the sequence from nucleotide 755 to 1275 and
nucleotides 1984 to 2297 fused in-frame. The resulting
DNA product of 833 nucleotides was cloned into the
pCR2.1 Topo vector and designated as pCR2.1-∆KIX. An
SphI-NotI DNA fragment obtained from pCR2.1-∆KIX and
was inserted into pCI-p300N that had been predigested
with SphI and NotI. The borders of construct no. 5 are
shown in Fig. 1 and the expressed recombinant protein
had the expected size. p300-C/H1-∆KIX (no. 6) was con-
structed by inserting the SphI/NotI DNA fragment from
pGEX-C/H1 (35) into pCI-p300N digested with SphI/NotI
for expression of residues 1 to 424 of p300. Construct no.
7 (Fig. 1) was constructed by digesting pCI-p300N with
SphI and re-ligating the larger fragment for the expression
of residues 1 through 347 of p300. Finally, p300∆N-∆C/
H1-∆KIX was constructed from pCI-p300N by digesting
with MunI and re-ligated to express residues 1 to 196 of
p300. Bacterial plasmids coding for glutathion-S-trans-
ferase (GST) fusion proteins pGST-C/H1 (328–424) and
pGST-KIX (436–661) (Fig. 1) were constructed from
pGEX-6p-2GST-p300 [30] and grown in E. coli, BL21 cells.
pCR3.1-FLAG-SRC-1a was grown in E. coli, JM109 cells
[24]. Human 293T or HeLa cells were cultivated in DMEM
medium supplemented with 1% penicillin and strepto-
mycin, 1% Glutamine and 10 % fetal calf serum.
Plasmid p300FL was transfected into 293T cells and met-
abolically labeled with L-[35S]-Methionine plus L-[35S]-
Cysteine (spec. act. of 37 TBq/mM, PRO-MIX, Amersham)
for 6 hr. Cells were harvested and used for
immunoprecipitation as described above. The precipitates
were analyzed by SDS-PAGE on 12% gels, dried, and
exposed on KODAK Biomax MR1 films.
Luc reporter gene expression assays
Plasmid pCMV-βgal directing β-galactosidase expression
from the CMV-IE promoter was used for normalization of
transfection efficiency. Luc reporter gene assays were per-
formed and quantified as described [31] using a
Luminoskan TL Plus luminometer (Labsystems, Frank-
furt, FRG). pUC18 vector plasmid DNA was used as carrierBMC Molecular Biology 2004, 5:16 http://www.biomedcentral.com/1471-2199/5/16
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DNA to equalize the DNA concentration of each transfec-
tion. Cells were harvested 18 h after transfection. The
results of luc assays were based upon at least triplicate
experiments on multiple independent occasions. Expres-
sion levels were monitored by Western blot analysis.
Co-immunoprecipitation
Immunoprecipitation was performed as described previ-
ously with minor modifications [32]. Lysates of subcon-
fluent cotransfected layer of 293T cells were prepared by
first washing the cells with PBS, and subsequently lysed in
lysis buffer (150 mM NaCl, 20 mM Tris-HCl [pH 7.5], 1
mM phenylmethylsulfonyl-fluoride containing 1% (v/v)
Triton X-100. To inhibit unspecific protease activity, pro-
tease inhibitors (Biomol) were added to the lysis buffer.
Lysates were precleared with protein A-SepharoseCL-4B
(Amersham Bioscience AB, Uppsala). Co-immunoprecip-
itation of p300FL, p300N, p300M, p300C, SRC-1, and
PCAF were performed with rabbit anti Bel1 antiserum
[23]. The immune precipitates were retrieved with protein
A-SepharoseCL-4B (Pharmacia) and eluted by boiling. To
detect the specific precipitate, immunoblotting was per-
formed with specific antibodies against expressed p300,
shortened p300 versions, and SRC-1. For the detection of
expressed PCAF, Western blot analysis with monoclonal
anti-FLAG antibody was carried out. The immunoprecipi-
tates were washed three times with the lysis buffer and
analyzed by immunoblotting on 12% gels for expressed
p300FL and on 14% gels for shortened p300 forms, PCAF,
and SRC-1a. The experiments were repeated at least three
times, specially the immunoprecipitations of lysates of
p300C-transfected cells.
GST pull-down assays
The recombinant GST-C/H1 and GST-KIX proteins were
expressed in E. coli BL21/DE3 cells after transformation
with the corresponding plasmids. Expressed proteins were
purified by binding to glutathione Sepharose 4B resin.
Each of the GST-fusion proteins bound to glutathione
Sepharose 4B were mixed with lysates obtained from
pbel1s-transfected 293T cells. After incubation at 4°C
overnight in binding buffer [30] and extensive washing
with the binding buffer, bound proteins were eluted,
separated by SDS-PAGE, and visualized by staining with
Coomassie Brilliant Blue according to Ariumi [30] or
detected by Western blot analysis.
Immunoblotting
Cells were harvested two days after transfection by lysis in
1% SDS and the protein concentration was determined
using the DC protein assay (BioRad). Identical amounts
of proteins were separated by SDS-PAGE on 12% gels,
blotted, reacted with monoclonal serum directed against
the FLAG epitope of the four different FLAG-tagged p300
(Sigma), or polyclonal serum direct against Bel1 [23], and
detected by enhanced chemoluminescence.
List of abbreviations used
CBP, CREB-binding protein; C/H1, 2, and 3, Cys/His-rich
domains of p300; FL, full-length; HAT, histone acetyl-
transferase; LTR, long terminal repeat; luc, luciferase;
PCAF, p300/CBP-associated factor; Q, Glutamine-rich
domain of p300; SRC, steroid receptor coactivator;
p300N, p300M, and p300C, amino-, middle and C-termi-
nal regions of p300; PFV, primate foamy virus; IP.BRE,
internal promoter Bel1 response element; TAD, trans-acti-
vation domain; NF1, nuclear factor 1; CMV, cytomegalo-
virus; GST, glutathione-S-transferase.
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